Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells

Abstract excerpt

KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogenic driver with mutations in 30% of non-small cell lung cancer (NSCLC). However, there is no effective clinical drug even though it has been identified as an oncogene for 30 years. In this study, we identified a small molecule inhibitor compound 0375-0604 targeting KRAS by using molecular docking based virtual screening approach. Compound...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cytokine Signaling Pathways and Interactions
• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Protein Kinase Regulation and GTPase Signaling